These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 29616116)

  • 1. Lenalidomide improvement of cisplatin antitumor efficacy on triple-negative breast cancer cells
    Yin LL; Wen XM; Lai QH; Li J; Wang XW
    Oncol Lett; 2018 May; 15(5):6469-6474. PubMed ID: 29616116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2.
    Gao Z; Shi M; Wang Y; Chen J; Ou Y
    Pathol Res Pract; 2019 Jul; 215(7):152422. PubMed ID: 31079851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immunomodulatory drug lenalidomide restores a vitamin D sensitive phenotype to the vitamin D resistant breast cancer cell line MDA-MB-231 through inhibition of BCL-2: potential for breast cancer therapeutics.
    Brosseau C; Colston K; Dalgleish AG; Galustian C
    Apoptosis; 2012 Feb; 17(2):164-73. PubMed ID: 22109882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
    Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
    Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of cisplatin and bromelain exerts synergistic cytotoxic effects against breast cancer cell line MDA-MB-231 in vitro.
    Pauzi AZ; Yeap SK; Abu N; Lim KL; Omar AR; Aziz SA; Chow AL; Subramani T; Tan SG; Alitheen NB
    Chin Med; 2016; 11():46. PubMed ID: 27891174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
    Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
    BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additive Pharmacological Interaction between Cisplatin (CDDP) and Histone Deacetylase Inhibitors (HDIs) in MDA-MB-231 Triple Negative Breast Cancer (TNBC) Cells with Altered Notch1 Activity-An Isobolographic Analysis.
    Wawruszak A; Luszczki JJ; Kalafut J; Okla K; Halasa M; Rivero-Muller A; Stepulak A
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31357442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pioglitazone enhances cisplatin's impact on triple-negative breast cancer: Role of PPARγ in cell apoptosis.
    Alqahtani QH; Alkharashi LA; Alajami H; Alkharashi I; Alkharashi L; Alhinti SN
    Saudi Pharm J; 2024 May; 32(5):102059. PubMed ID: 38601974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer.
    Liu J; Chen X; Ward T; Pegram M; Shen K
    Tumour Biol; 2016 Jul; 37(7):9825-35. PubMed ID: 26810188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted Inhibition of miR-221/222 Promotes Cell Sensitivity to Cisplatin in Triple-Negative Breast Cancer MDA-MB-231 Cells.
    Li S; Li Q; Lü J; Zhao Q; Li D; Shen L; Wang Z; Liu J; Xie D; Cho WC; Xu S; Yu Z
    Front Genet; 2019; 10():1278. PubMed ID: 32010177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CXCL13 inhibition induce the apoptosis of MDA-MB-231 breast cancer cells through blocking CXCR5/ERK signaling pathway.
    Ma JJ; Jiang L; Tong DY; Ren YN; Sheng MF; Liu HC
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8755-8762. PubMed ID: 30575916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin-resistant MDA-MB-231 Cell-derived Exosomes Increase the Resistance of Recipient Cells in an Exosomal miR-423-5p-dependent Manner.
    Wang B; Zhang Y; Ye M; Wu J; Ma L; Chen H
    Curr Drug Metab; 2019; 20(10):804-814. PubMed ID: 31424364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valproic acid reprograms the metabolic aberration of cisplatin treatment via ALDH modulation in triple-negative breast cancer cells.
    Granit Mizrahi A; Gugenheim A; Hamad H; Hamed R; Tetro N; Maimon O; Khutsurauli S; Nechushtan H; Nisman B; Duran D; Samman W; Birimberg-Schwartz L; Grunewald M; Eyal S; Peretz T
    Front Cell Dev Biol; 2023; 11():1217149. PubMed ID: 37954205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A.
    Choi SK; Kim HS; Jin T; Hwang EH; Jung M; Moon WK
    BMC Cancer; 2016 Aug; 16():570. PubMed ID: 27484639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib.
    Wang X; Song H; Yu Q; Liu Q; Wang L; Liu Z; Yu Z
    Oncol Rep; 2015 Feb; 33(2):526-32. PubMed ID: 25501339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Silencing of TGIF sensitizes MDA-MB-231 human breast cancer cells to cisplatin-induced apoptosis.
    Pan T; Mao T; Yang H; Wang H; Wang Y
    Exp Ther Med; 2018 Mar; 15(3):2978-2984. PubMed ID: 29456703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triptolide Decreases Cell Proliferation and Induces Cell Death in Triple Negative MDA-MB-231 Breast Cancer Cells.
    Varghese E; Samuel SM; Varghese S; Cheema S; Mamtani R; Büsselberg D
    Biomolecules; 2018 Dec; 8(4):. PubMed ID: 30563138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic effects of combined cisplatin and
    Abu Bakar NFAB; Yeo ZL; Hussin F; Madhavan P; Lim V; Jemon K; Prabhakaran P
    J Taibah Univ Med Sci; 2023 Dec; 18(6):1220-1236. PubMed ID: 37250812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long noncoding RNA HCP5 contributes to cisplatin resistance in human triple-negative breast cancer via regulation of PTEN expression.
    Wu J; Chen H; Ye M; Wang B; Zhang Y; Sheng J; Meng T; Chen H
    Biomed Pharmacother; 2019 Jul; 115():108869. PubMed ID: 31028999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.